Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT06769256

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06769256
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06769256. Randomized; single masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2027-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
Acronym
H2-THROMBUS
Condition
ST-segment Elevation Myocardial Infarction (STEMI)
Intervention (Drug)
rhTNK-tPA, 4-8 mg
Intervention (Drug)
Tirofiban
Lead sponsor
Henan Institute of Cardiovascular Epidemiology (class: other)

Record details

Record id
cardio:ct-nct06769256
Content hash
fa4e25ea16093b00435007a717553c798b9d114c1d4a333642fd317502784068